.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE08_Atazanavir.Atazanavir

Information

Atazanavir is an antiretroviral medication used in combination with other medications to treat and prevent HIV/AIDS. It is a protease inhibitor and is commonly administered orally. Atazanavir is approved by regulatory authorities such as the FDA and continues to be used clinically today.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers at steady-state after oral administration of atazanavir 400 mg once daily, fasted state.

References

1. Solas, C, et al., & Simon, N (2008). Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Therapeutic drug monitoring 30(6) 670–673. DOI:10.1097/FTD.0b013e3181897bff PUBMED:https://pubmed.ncbi.nlm.nih.gov/18806695

2. Dickinson, L, et al., & Aarons, L (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. The Journal of antimicrobial chemotherapy 63(6) 1233–1243. DOI:10.1093/jac/dkp102 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19329800

3. Singkham, N, et al., & Punyawudho, B (2022). Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients. Expert review of clinical pharmacology 15(1) 99–108. DOI:10.1080/17512433.2022.2000858 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34727835

Revisions

• 06/2025 initial generated model